Emeren Group Ltd: Nasdaq/NYSE listing notice — Emeren Group receives NYSE non-compliance notice for late 10-K filing due to auditor resignation

Emeren Group Ltd

NYSE notified Emeren on April 17, 2024 of non-compliance under Section 802.01E for failure to timely file FY2023 10-K.
Company has six months, until October 16, 2024, to file and regain compliance; possible six-month extension.
Non-compliance stems from independent auditor resignation (disclosed April 2, 2024) and ongoing transition to new auditor.
NYSE may commence delisting proceedings at any time if circumstances warrant, but listing is not immediately affected.
Emeren (NYSE: SOL) is a global solar project developer, owner, and operator.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Emeren Group Ltd received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

Exchange: nyse
Notice: noncompliance notice
Deficiency: late filing
Rules: 802.01E

Exact text from the filing

April 17, 2024, Emeren Group Ltd (the “Company”) received a notice from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria outlined in Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. As previously disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 2, 2024, the Company was notified by its indep

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-049521

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.